• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer

June 2, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
woman patient
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


woman patient
Credit: Unsplash/CC0 Public Domain

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful improvement in survival for patients with advanced endometrial cancer, but also improves the quality of that extended survival by minimizing the time spent suffering from disease symptoms or severe treatment side effects.

The international team found patients who received the dostarlimab combination treatment gained at least 10% more high quality-adjusted time without symptoms of disease progression or toxicity of treatment, a comprehensive measure that accounts for survival, treatment side effects and patient-reported well-being, compared to those treated with chemotherapy alone. In some cases, this translated to as much as 5.5 additional months of extended, high-quality life.

Notably, the study found that although more patients in the dostarlimab arm experienced serious side effects (grade 3 or higher), the overall benefit of extended, high-quality survival outweighed the risks. Immune-related complications were effectively managed, and most serious side effects occurred early during treatment.

The work is published in the International Journal of Gynecological Cancer.

Dostarlimab is an anti-PD-1 checkpoint inhibitor, a type of immunotherapy that helps the immune system recognize and attack cancer cells. It was previously shown in the phase 3 clinical trial known as RUBY to improve progression-free and overall survival in patients with advanced or recurrent endometrial cancer. However, these endpoints did not consider patient quality of life.

This new analysis of the RUBY trial, which enrolled 494 adults with advanced or recurrent endometrial cancer unlikely to be cured by surgery or radiation, looked beyond how long patients lived and focused on how they felt during that time.

Researchers used data from the first interim analysis to evaluate how the treatment affected quality-adjusted time without symptoms or side effects. They calculated this by dividing each patient’s time into three states: time with side effects, time without symptoms or side effects, and time after the cancer progressed.

Quality of life data was collected through patient questionnaires at multiple timepoints. Statistical methods, including survival analysis and utility scoring, were used to compare the two treatment groups.

Impact

The study suggests that dostarlimab plus chemotherapy not only helps patients live longer but preserves the quality of that time, further supporting its use as a new standard of care for advanced or recurrent endometrial cancer.

“This is the first study to demonstrate a statistically significant improvement in both overall survival and quality-adjusted survival with an immunotherapy-chemotherapy combination in this disease setting,” said Dr. Dana Chase, a professor of obstetrics and gynecology in the division of gynecologic oncology at the David Geffen School of Medicine at UCLA and first author of the study. “It’s a major step forward in the treatment of endometrial cancer.”

The study was supported by GSK, a British multinational pharmaceutical and biotechnology company.

More information:
Dana M. Chase et al, Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel, International Journal of Gynecological Cancer (2025). DOI: 10.1016/j.ijgc.2025.101935

Provided by
University of California, Los Angeles


Citation:
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer (2025, June 2)
retrieved 2 June 2025
from https://medicalxpress.com/news/2025-06-adding-immunotherapy-standard-chemotherapy-quality.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



woman patient
Credit: Unsplash/CC0 Public Domain

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful improvement in survival for patients with advanced endometrial cancer, but also improves the quality of that extended survival by minimizing the time spent suffering from disease symptoms or severe treatment side effects.

The international team found patients who received the dostarlimab combination treatment gained at least 10% more high quality-adjusted time without symptoms of disease progression or toxicity of treatment, a comprehensive measure that accounts for survival, treatment side effects and patient-reported well-being, compared to those treated with chemotherapy alone. In some cases, this translated to as much as 5.5 additional months of extended, high-quality life.

Notably, the study found that although more patients in the dostarlimab arm experienced serious side effects (grade 3 or higher), the overall benefit of extended, high-quality survival outweighed the risks. Immune-related complications were effectively managed, and most serious side effects occurred early during treatment.

The work is published in the International Journal of Gynecological Cancer.

Dostarlimab is an anti-PD-1 checkpoint inhibitor, a type of immunotherapy that helps the immune system recognize and attack cancer cells. It was previously shown in the phase 3 clinical trial known as RUBY to improve progression-free and overall survival in patients with advanced or recurrent endometrial cancer. However, these endpoints did not consider patient quality of life.

This new analysis of the RUBY trial, which enrolled 494 adults with advanced or recurrent endometrial cancer unlikely to be cured by surgery or radiation, looked beyond how long patients lived and focused on how they felt during that time.

Researchers used data from the first interim analysis to evaluate how the treatment affected quality-adjusted time without symptoms or side effects. They calculated this by dividing each patient’s time into three states: time with side effects, time without symptoms or side effects, and time after the cancer progressed.

Quality of life data was collected through patient questionnaires at multiple timepoints. Statistical methods, including survival analysis and utility scoring, were used to compare the two treatment groups.

Impact

The study suggests that dostarlimab plus chemotherapy not only helps patients live longer but preserves the quality of that time, further supporting its use as a new standard of care for advanced or recurrent endometrial cancer.

“This is the first study to demonstrate a statistically significant improvement in both overall survival and quality-adjusted survival with an immunotherapy-chemotherapy combination in this disease setting,” said Dr. Dana Chase, a professor of obstetrics and gynecology in the division of gynecologic oncology at the David Geffen School of Medicine at UCLA and first author of the study. “It’s a major step forward in the treatment of endometrial cancer.”

The study was supported by GSK, a British multinational pharmaceutical and biotechnology company.

More information:
Dana M. Chase et al, Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel, International Journal of Gynecological Cancer (2025). DOI: 10.1016/j.ijgc.2025.101935

Provided by
University of California, Los Angeles


Citation:
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer (2025, June 2)
retrieved 2 June 2025
from https://medicalxpress.com/news/2025-06-adding-immunotherapy-standard-chemotherapy-quality.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Baltimore schools sued for failing to protect students from a predatory teacher

Related Posts

Why You Should Seek Immediate Medical Care After a Car Crash

June 2, 2025
4
Contributed: Reimagining therapeutic cornerstones for the immersive age

Contributed: Reimagining therapeutic cornerstones for the immersive age

June 2, 2025
4
  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Baltimore schools sued for failing to protect students from a predatory teacher

Baltimore schools sued for failing to protect students from a predatory teacher

June 2, 2025

Michael Cohen: Trump will ‘go after Elon’s money next’

June 2, 2025
Impeachment trial up to next Congress

Impeachment trial up to next Congress

June 2, 2025
Who is Poland's President-elect Karol Nawrocki? – DW – 06/02/2025

Who is Poland’s President-elect Karol Nawrocki? – DW – 06/02/2025

June 2, 2025

Recent News

Baltimore schools sued for failing to protect students from a predatory teacher

Baltimore schools sued for failing to protect students from a predatory teacher

June 2, 2025
0

Michael Cohen: Trump will ‘go after Elon’s money next’

June 2, 2025
1
Impeachment trial up to next Congress

Impeachment trial up to next Congress

June 2, 2025
4
Who is Poland's President-elect Karol Nawrocki? – DW – 06/02/2025

Who is Poland’s President-elect Karol Nawrocki? – DW – 06/02/2025

June 2, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Baltimore schools sued for failing to protect students from a predatory teacher

Baltimore schools sued for failing to protect students from a predatory teacher

June 2, 2025

Michael Cohen: Trump will ‘go after Elon’s money next’

June 2, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co